12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19 : A Single-Center Prospective Cohort Study
Copyright © 2022 Liao, Li, Ma, Zhang, Zheng, Li, Li, Liu and Zhang..
Objective: The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase.
Methods: A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups.
Results: Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up.
Conclusion: In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Frontiers in cellular and infection microbiology - 12(2022) vom: 25., Seite 864933 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liao, Xuejiao [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alanine aminotransferase (ALT) |
|---|
| Anmerkungen: |
Date Completed 03.05.2022 Date Revised 23.07.2022 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.3389/fcimb.2022.864933 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340225068 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340225068 | ||
| 003 | DE-627 | ||
| 005 | 20231226004650.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fcimb.2022.864933 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1134.xml |
| 035 | |a (DE-627)NLM340225068 | ||
| 035 | |a (NLM)35493732 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liao, Xuejiao |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 12-Month Post-Discharge Liver Function Test Abnormalities Among Patients With COVID-19 |b A Single-Center Prospective Cohort Study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.05.2022 | ||
| 500 | |a Date Revised 23.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Liao, Li, Ma, Zhang, Zheng, Li, Li, Liu and Zhang. | ||
| 520 | |a Objective: The longitudinal effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the liver are unknown. This study aimed to characterize dynamic changes in liver function test abnormalities in patients with COVID-19 at the acute phase and recovery phase | ||
| 520 | |a Methods: A prospective cohort study involved patients with COVID-19 who were admitted to Shenzhen Third People's Hospital between January 11, 2020, and April 27, 2020. Patients underwent liver function tests at hospitalization and at the outpatient visit at the 1-month, 3-month, 6-month, and 12-month follow-ups | ||
| 520 | |a Results: Among 461 patients, 28.4% of patients had any kind of liver function tests abnormality at admission, manifested as elevated ALT (13.0%), AST (17.6%), and GGT (15.8%) levels. The trajectory analysis indicated a marked improvement in liver function after discharge, with any kind of liver function test abnormalities of 25.1% at 1 month, 13.2% at 3 months, 16.7% at 6 months, and 13.2% at 12 months after discharge. Persistent liver function abnormalities were observed in patients with pre-existing conditions during follow-up. A significantly higher prevalence of ultrasound determined fatty liver disease was found in those patients with more frequent LFT abnormalities at follow-up | ||
| 520 | |a Conclusion: In this study of patients with COVID-19, liver damage in COVID-19 was usually temporary and could return to normal at the end of the 12-month follow-up | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a alanine aminotransferase (ALT) | |
| 650 | 4 | |a albumin | |
| 650 | 4 | |a aspartate aminotransferase (AST) | |
| 650 | 4 | |a gamma-glutamyltransferase (GGT) | |
| 700 | 1 | |a Li, Dapeng |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Zhenghua |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lina |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Baoqi |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Zhiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guobao |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zheng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in cellular and infection microbiology |d 2011 |g 12(2022) vom: 25., Seite 864933 |w (DE-627)NLM220414289 |x 2235-2988 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g day:25 |g pages:864933 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fcimb.2022.864933 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |b 25 |h 864933 | ||